AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02026817
Drug: Metformin SR 750mg
RxNorm normalized name: metformin hydrochloride 750 MG
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Co-administration of Metformin 750mg and Rosuvastatin 10mg orally in the morning on day1 or day8.
Trial: NCT03565068
Drug: MK-8189
RxNorm normalized name: MK-8189
DrugBank: MK-8189 (DB19153)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-8189 4 mg tablet(s) will be administered orally QD for a total daily dose of 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 36 mg or 48 mg.
Trial: NCT03831334
Drug: oral minoxidil
RxNorm normalized name: minoxidil Oral Tablet
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be provided with minoxidil (2.5 mg tablets) for 90 days (45 tablets + 5 extra in case of splitting difficulty) of treatment drug in dispensing containers and instructed to take half a pill (1.25mg), once a day.
Trial: NCT03936335
Drug: dupilumab
RxNorm normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: No study drug will be administered. This study is based on an analysis of automated medical and prescription claims, supplemented by information abstracted from the medical record.
Trial: NCT04855617
Drug: Ocrelizumab
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administer Ocrelizumab under the close supervision of an experienced healthcare professional with access to appropriate medical support to manage severe reactions such as serious infusion reactions.~* Initial dose: 300 mg intravenous infusion, followed two weeks later by a second 300 mg intravenous infusion.~* Subsequent doses: single 600 mg intravenous infusion every 6 months.~* Observe the patient for at least one hour after the completion of the infusion
Trial: NCT02291861
Drug: SD-809
RxNorm normalized name: Alphanine SD
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SD-809 tablets dose titrated for 4 weeks until target randomized dose is reached. The dose is maintained for an additional 8 weeks. Tablets were swallowed whole with water and taken with food.
Trial: NCT02211690
Drug: dolutegravir 50 mg (one tablet daily)
RxNorm normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02211690
Drug: emtricitabine-tenofovir 300/200 mg (one tablet daily)
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03017326
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arms A and B - cisplatin is used alone Arms C, D, E and F - cisplatin us used in combination
Trial: NCT01974258
Drug: Cobimetinib
RxNorm normalized name: Cobimetinib
DrugBank: Cobimetinib (DB05239)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Escalating dose
Trial: NCT03017326
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arms C and D used in combination
Trial: NCT00711828
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT00711828
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT01756105
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin: from 500 mg 2 time per day to 2500 mg per day; with increment of 500 mg every 5 days until abstention of
Trial: NCT03017326
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arms C and D used in combination
Trial: NCT03017326
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arm D used in combination
Trial: NCT03017326
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arm D used in combination
Trial: NCT03017326
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arm F used in combination
Trial: NCT03017326
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arm F used in combination
Trial: NCT03017326
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arm used in combination
Trial: NCT01435655
Drug: tafamidis
RxNorm normalized name: Tafamidis
DrugBank: Tafamidis (DB11644)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: tafamidis meglumine 20 mg QD
Trial: NCT04045730
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All patients will receive treatment with gemcitabine, nab-paclitaxel, PVHA, and pembrolizumab.
Trial: NCT02378740
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The study drug (either ketamine or saline) will be administered from the beginning of anesthesia through the commencement of wound closure to provide the following dose of ketamine:~0.5 mg/kg loading dose 8.3 mcg/kg/min (0.5 mg/kg/hr) infusion
Trial: NCT02378740
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The study drug (either ketamine or saline) will be administered from the beginning of anesthesia through the commencement of wound closure to provide the following dose of ketamine:~0.5 mg/kg loading dose 8.3 mcg/kg/min (0.5 mg/kg/hr) infusion
Trial: NCT01870388
Drug: Baricitinib
RxNorm normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered orally
Trial: NCT01974258
Drug: Cobimetinib
RxNorm normalized name: Cobimetinib
DrugBank: Cobimetinib (DB05239)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Orally administered once daily for 21 consecutive days, followed by 7 days off.
Trial: NCT03051698
Drug: C1-inhibitor
RxNorm normalized name: c1-inhibitor, plasma derived
DrugBank: Human C1-esterase inhibitor (DB06404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 Unit/kg IV, one gift prior to broncho provocation.
Trial: NCT02115074
Drug: Fluvastatine
RxNorm normalized name: fluvastatine
DrugBank: Fluvastatin (DB01095)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Escalation dose : Level 1: 2mg/kg/day. Level 2: 4mg/kg/day. Level 3: 6mg/kg/day. Level 4: 8mg/kg/day.~Per os from D1 to D14 of each 28 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops.
Trial: NCT02115074
Drug: Celebrex
RxNorm normalized name: Celebrex
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose levels : 100 mg twice a day (\< 20 kg), 200 mg twice a day (20-50 kg), 400 mg twice a day (\> 50 kg)~Per os from D1 to D28 of each 28 day cycle.~Number of Cycles: until progression or unacceptable toxicity develops.
Trial: NCT01974258
Drug: Onartuzumab
RxNorm normalized name: Onartuzumab
DrugBank: Onartuzumab (DB11746)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by IV infusion every 2 weeks
Trial: NCT01974258
Drug: Vemurafenib
RxNorm normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orally administered twice daily
Trial: NCT01918033
Drug: Desloratadine 5 mg
RxNorm normalized name: desloratadine 5 MG
DrugBank: Desloratadine (DB00967)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desloratadine 5 mg tablets
Trial: NCT00423189
Drug: Ranibizumab (Lucentis)
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: as needed, one intravitreal injection of 0.50mg ranibizumab
Trial: NCT02286648
Drug: Formocresol
RxNorm normalized name: Formocresol
DrugBank: Cresol (DB11143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pulpotomy with formocresol
Trial: NCT02286648
Drug: Mineral Trioxide Aggregate
RxNorm normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pulpotomy with MTA
Trial: NCT03407703
Drug: Elbasvir / Grazoprevir Oral Tablet [Zepatier]
RxNorm normalized name: elbasvir / grazoprevir Oral Tablet [Zepatier]
DrugBank: Elbasvir (DB11574)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HCV treatment
Trial: NCT02028403
Drug: BMS-936559
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 0.3 mg/kg, 1 mg/kg, 3 mg/kg, or 10 mg/kg of BMS-936559, depending on which cohort participants are enrolled in, administered as an intravenous (IV) infusion
Trial: NCT03847545
Drug: Fampridine
RxNorm normalized name: FAMPRIDINE
DrugBank: Dalfampridine (DB06637)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sustained-release tablet 10 mg morning and evening.
Trial: NCT02802111
Drug: Albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient receives albuterol 5 mg aerosolized. Oxygen consumption and vital signs are measured for 1 hour after intervention.
Trial: NCT02802111
Drug: Levalbuterol
RxNorm normalized name: Levalbuterol
DrugBank: Levosalbutamol (DB13139)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient receives levalbuterol 2.5 mg aerosolized. Oxygen consumption and vital signs are measured for 1 hour after intervention
Trial: NCT01407874
Drug: Ulodesine (BCX4208) 5 mg
RxNorm normalized name: undecylenate
DrugBank: Ulodesine (DB12353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose administered daily for 84 days.
Trial: NCT01407874
Drug: Ulodesine (BCX4208) 10 mg
RxNorm normalized name: undecylenate
DrugBank: Ulodesine (DB12353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose administered daily for 84 days.
Trial: NCT00088166
Drug: hCRF
RxNorm normalized name: hCRF
DrugBank: Corticorelin (DB05394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hCRF ; open-label dexamethasone that the patient is currently taking
Trial: NCT04884191
Drug: Pacritinib
RxNorm normalized name: Pacritinib
DrugBank: Pacritinib (DB11697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pacritinib
Trial: NCT01976507
Drug: dabigatran etexilate mesylate
RxNorm normalized name: Dabigatran Etexilate Mesylate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediately following the ablation procedure (4-6 hours after sheath pull and vascular hemostasis), dabigatran etexilate 150mg bid, or 75mg twice daily based on creatinine clearance in the Use in Specified Populations (USPI), will be administered for a minimum of 3 months post RF ablation.
Trial: NCT02566603
Drug: PRTX-100
RxNorm normalized name: PRTX-100
DrugBank: PRTX-100 (DB05947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four weekly infusions of PRTX-100 at a level of 3 micrograms of PRTX-100 per kilogram of patient weight, infused over 30 minutes, followed by four hours of observation after start of infusion.
Trial: NCT02566603
Drug: PRTX-100
RxNorm normalized name: PRTX-100
DrugBank: PRTX-100 (DB05947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four weekly infusions of PRTX-100 at a level of 6 micrograms of PRTX-100 per kilogram of patient weight, infused over 30 to 60 minutes, followed by four hours of observation after start of infusion.
Trial: NCT03695185
Drug: Ravagalimab 600 mg
RxNorm normalized name: Ravagalimab
DrugBank: Ravagalimab (DB16676)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ravagalimab 600 mg was administered intravenously (IV).
Trial: NCT03695185
Drug: Ravagalimab 300 mg
RxNorm normalized name: Ravagalimab
DrugBank: Ravagalimab (DB16676)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ravagalimab 300 mg was administered subcutaneously (SC).
Trial: NCT02137785
Drug: Topical Solution Vehicle
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light
Trial: NCT02566603
Drug: PRTX-100
RxNorm normalized name: PRTX-100
DrugBank: PRTX-100 (DB05947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four weekly infusions of PRTX-100 at a level of 12 micrograms of PRTX-100 per kilogram of patient weight, infused over 60 minutes, followed by four hours of observation after start of infusion.
Trial: NCT02566603
Drug: PRTX-100
RxNorm normalized name: PRTX-100
DrugBank: PRTX-100 (DB05947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four weekly infusions of PRTX-100 at a level of 18 micrograms of PRTX-100 per kilogram of patient weight, infused over 60 minutes, followed by four hours of observation after start of infusion.
Trial: NCT02566603
Drug: PRTX-100
RxNorm normalized name: PRTX-100
DrugBank: PRTX-100 (DB05947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four weekly infusions of PRTX-100 at a level of 24 micrograms of PRTX-100 per kilogram of patient weight, infused over 60 minutes, followed by four hours of observation after start of infusion.
Trial: NCT00276679
Drug: temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04723979
Drug: Eptacog alfa
RxNorm normalized name: Eptacog alfa
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant coagulation factor VII activated
Trial: NCT01844206
Drug: Epidural Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be given 3mg epidural morphine, 24 hours after the initial dose.
Trial: NCT00723190
Drug: CLONICEL (Clonidine HCl sustained release)
RxNorm normalized name: clonidine hydrochloride Extended Release Suspension
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.1 mg for 1 week; the dose may be escalated to 0.2 mg/day at week 2, 0.3 mg/day at week 3, and 0.4 mg/day at week 4
Trial: NCT03502018
Drug: Bupivacaine liposome
RxNorm normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A long-acting liposomal bupivacaine
Trial: NCT03502018
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline injection used as control
Trial: NCT00691899
Drug: odanacatib
RxNorm normalized name: Odanacatib
DrugBank: Odanacatib (DB06670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: odanacatib; 5mg oral, once daily for Approximately 36 months.
Trial: NCT03730038
Drug: Treatment of pitavastatin 4 mg qd for 12 weeks
RxNorm normalized name: pitavastatin
DrugBank: Pitavastatin (DB08860)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment of pitavastatin 4 mg qd for 12 weeks
Trial: NCT03912818
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03912818
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03912818
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03912818
Drug: Vinblastine
RxNorm normalized name: Vinblastine
DrugBank: Vinblastine (DB00570)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00431665
Drug: NG-monomethyl-L-Arginine (L-NMMA)
RxNorm normalized name: NG-Monomethyl-L-arginine
DrugBank: Tilarginine (DB11815)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00431665
Drug: triglycerides (Intralipid 20%)
RxNorm normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00431665
Drug: somatostatin
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00020527
Drug: caspofungin acetate
RxNorm normalized name: Caspofungin Acetate
DrugBank: Caspofungin (DB00520)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00431665
Drug: insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00431665
Drug: glucose
RxNorm normalized name: Glucose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00431665
Drug: inulin
RxNorm normalized name: Inulin
DrugBank: Inulin (DB00638)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00431665
Drug: paraamino hippurate (PAH)
RxNorm normalized name: hippurate
DrugBank: Iodohippurate sodium I-131 (DB09382)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02400567
Drug: Epirubicin
RxNorm normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02400567
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02400567
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03052998
Drug: Ivermectin
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Effect of Ivermectin on frequency of seizures
Trial: NCT01445405
Drug: Bortezomib (Velcade, PS-341)
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01445405
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01445405
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02000414
Drug: intraperitoneal daptomycin
RxNorm normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intraperitoneal daptomycin administartion and study of daptomycin kinetics
Trial: NCT01814059
Drug: sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03295552
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: decitabine 7mg/m2, d1-d5, q3w
Trial: NCT03295552
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: carboplatin AUC = 6, d6, q3w
Trial: NCT00388336
Drug: Epoetin Alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00785434
Drug: escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose ranging up to 50mg
Trial: NCT01099514
Drug: Nilotinib
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D1\~ Nilotinib 400 mg (2 capsules) PO BID q 28 days
Trial: NCT02092558
Drug: Second-generation cephalosporin, nitrofurantoin, 1% aminoglycoside solution
DrugBank: Nitrofurantoin (DB00698)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02092558
Drug: cephalosporin with chemotherapeutics
RxNorm normalized name: Primatene with ephedrine Pill
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second-generation cephalosporin was prescribed for 10 days, and then treatment crossover with chemotherapeutics in therapeutic dose (change in every week) during 3 months
Trial: NCT00836602
Drug: BMS-779788
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral Solution, Oral, 1 mg, Once daily, 7 days
Trial: NCT03817411
Drug: Telatinib
RxNorm normalized name: Telatinib
DrugBank: Telatinib (DB15393)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg tablets, 900 mg twice daily (BID) at 12h-intervals.
Trial: NCT03817411
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 130 mg/m2, administered intravenously over 2 hours, on Day 1 every 3 weeks (one administration per cycle) for a maximum of 6 cycles.
Trial: NCT00836602
Drug: BMS-779788
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral Solution, Oral, 2 mg, Once daily, 7 days
Trial: NCT00836602
Drug: BMS-779788
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral Solution, Oral, \<= 4 mg, Once daily, 7 days
Trial: NCT03916744
Drug: Giredestrant
RxNorm normalized name: Giredestrant
DrugBank: Giredestrant (DB19125)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Giredestrant will be administered orally once daily (QD) starting on Day 1 up to and including the day of surgery (if allowed per local process) on Day 15 (+/-2 days).
Trial: NCT00161070
Drug: aspirin and dipyridamole
RxNorm normalized name: Aspirin and dipyridamole only product
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00161070
Drug: aspirin alone
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01865916
Drug: Polyethylene Glycol (PEG) and 15 mg Bisacodyl
RxNorm normalized name: polyethylene glycols 0.15 MG/MG
DrugBank: Bisacodyl (DB09020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will be asked to take split dose of 2L PEG and 3 tablets of 5 mg Bisacodyl